Oral medicine used to treat uterine hypothetical disease – also known as endometriosis – has obtained approval to use by the UK National Health Service. Treatment gives hope to women who suffer from this exhausted condition.
Complex therapy was approved in 2021 in the United States and the European Union to treat medium pain to the extreme associated with this disease in pre -menopause.
This medication consists of 3 compounds: Relugallix, Estradiol and Norethisterone, which is also known as the Rilogolix complex treatment or Ryeqo, which is the first drug with a long -term daily dose licensed for the treatment of migratory endometrium according For the British Independent newspaper.
What distinguishes the complex medicine?
This drug is distinguished from other treatments currently available in the form of injection as follows:
- It provides a faster effect than available treatments.
- It can be taken at home and this is the patients from the frequent clinic visits to receive the injection.
- The drug collects multiple hormones in one pill, as treatment works by blocking specific hormones that contribute to the endometrium of the uterine migratory, and provides the body with the necessary hormones.
- It restores hormone levels to normal faster when you stop eating it.
Exhausted pain and the effect on fertility
The condition of the endometriosis affects approximately 10% of women and girls who are of childbearing age worldwide. Infected with the endometrium, the migratory lining grows a tissue similar to the endometrium in other places of the reproductive system such as the ovaries and the fallopian tubes.
The endometrium can affect women at any age, even adolescents, and may cause exhausted pain and abundance in the menstrual cycle and exhaustion, and it can also have an impact on fertility, which greatly affects a woman’s personal and professional life.
The diagnosis of the condition usually takes 9 years of symptoms for the first time. This is due to the fact that the symptoms may resemble those associated with other conditions, such as fibroids, pelvic inflammatory disease, and irritable bowel syndrome.
“This new treatment is a possible qualitative shift in how we deal with the state of the endometrium in the UK, as it re -controls the pathological condition of the injuries while ensuring their benefit to them. Instead of going to clinics to receive injections, it is possible to take a daily tablet at home,” said Helen Knight, Director of Medical Evaluation at the National Institute for Excellence in Health Care in the United Kingdom.